Skip to main content
Erschienen in: Journal für Gynäkologische Endokrinologie/Schweiz 4/2019

15.11.2019 | Klimakterium und Menopause | Menopause

Bioidentische Hormone

verfasst von: Prof. Dr. med. Petra Stute

Erschienen in: Journal für Gynäkologische Endokrinologie/Schweiz | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

In den vergangenen Jahren ist der Einsatz von sog. bioidentischen Hormonen (BIH) weltweit immer populärer geworden. Die Hypothese ist, dass BIH besonders gut wirksam und verträglich seien, da sie identisch mit den vom Körper produzierten Hormonen sind. Ihre Anwendung sei mit keinerlei Risiken verbunden. Bei der Diskussion um BIH werden einige Begrifflichkeiten vermischt. So wird oftmals suggeriert, dass BIH nur als individuelle Rezeptur erhältlich seien. Jedoch gibt es zahlreiche BIH als von den Behörden (Swissmedic) regulierte und von den Krankenkassen übernommene Präparate auf dem Markt. Die Risiken einer Therapie mit BIH sind grösstenteils mit denen von synthetischen Hormonen vergleichbar. Weiterhin wird oftmals postuliert, dass die Dosierung von BIH anhand von Speichelhormonbestimmungen festgelegt werden solle. Allerdings ist bisher die Speichelhormondiagnostik der Sexualsteroide noch nicht ausreichend etabliert. Die Dosierung richtet sich vielmehr nach der Symptomatik. Der Artikel geht speziell auf die Wirksamkeit und Sicherheit von BIH ein.
Literatur
1.
Zurück zum Zitat Cirigliano M (2007) Bioidentical hormone therapy: a review of the evidence. J Womens Health (larchmt) 16(5):600–631CrossRef Cirigliano M (2007) Bioidentical hormone therapy: a review of the evidence. J Womens Health (larchmt) 16(5):600–631CrossRef
2.
Zurück zum Zitat Boothby LA, Doering PL, Kipersztok S (2004) Bioidentical hormone therapy: a review. Menopause 11(3):356–367CrossRef Boothby LA, Doering PL, Kipersztok S (2004) Bioidentical hormone therapy: a review. Menopause 11(3):356–367CrossRef
3.
Zurück zum Zitat Rosenthal MS (2008) The Wiley Protocol: an analysis of ethical issues. Menopause 15(5:1014–1022CrossRef Rosenthal MS (2008) The Wiley Protocol: an analysis of ethical issues. Menopause 15(5:1014–1022CrossRef
4.
Zurück zum Zitat Perovic D, Kopajtic B, Stankovic T (1975) Treatment of climacteric complaints with oestriol. Arzneimittelforschung 25(6):962–964PubMed Perovic D, Kopajtic B, Stankovic T (1975) Treatment of climacteric complaints with oestriol. Arzneimittelforschung 25(6):962–964PubMed
5.
Zurück zum Zitat Tzingounis VA, Aksu MF, Greenblatt RB (1978) Estriol in the management of the menopause. JAMA 239(16):1638–1641CrossRef Tzingounis VA, Aksu MF, Greenblatt RB (1978) Estriol in the management of the menopause. JAMA 239(16):1638–1641CrossRef
6.
Zurück zum Zitat Lauritzen C (1987) Results of a 5 years prospective study of estriol succinate treatment in patients with climacteric complaints. Horm Metab Res 19(11):579–584CrossRef Lauritzen C (1987) Results of a 5 years prospective study of estriol succinate treatment in patients with climacteric complaints. Horm Metab Res 19(11):579–584CrossRef
7.
Zurück zum Zitat Takahashi K, Manabe A, Okada M, Kurioka H, Kanasaki H, Miyazaki K (2000) Efficacy and safety of oral estriol for managing postmenopausal symptoms. Maturitas 34(2):169–177CrossRef Takahashi K, Manabe A, Okada M, Kurioka H, Kanasaki H, Miyazaki K (2000) Efficacy and safety of oral estriol for managing postmenopausal symptoms. Maturitas 34(2):169–177CrossRef
8.
Zurück zum Zitat Takahashi K, Okada M, Ozaki T, Kurioka H, Manabe A, Kanasaki H et al (2000) Safety and efficacy of oestriol for symptoms of natural or surgically induced menopause. Hum Reprod 15(5):1028–1036CrossRef Takahashi K, Okada M, Ozaki T, Kurioka H, Manabe A, Kanasaki H et al (2000) Safety and efficacy of oestriol for symptoms of natural or surgically induced menopause. Hum Reprod 15(5):1028–1036CrossRef
9.
Zurück zum Zitat Padwick ML, Siddle NC, Lane G, Endacott JA, Cooper H, Pryse-Davies J et al (1986) Oestriol with oestradiol verses oestradiol alone: a comparison of endometrial, symptomatic and psychological effects. Br J Obstet Gynaecol 93(6):606–612CrossRef Padwick ML, Siddle NC, Lane G, Endacott JA, Cooper H, Pryse-Davies J et al (1986) Oestriol with oestradiol verses oestradiol alone: a comparison of endometrial, symptomatic and psychological effects. Br J Obstet Gynaecol 93(6):606–612CrossRef
10.
Zurück zum Zitat Stephenson K, Neuenschwander PF, Kurdowska AK (2013) The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women. Int J Pharm Compd 17(1):74–85PubMed Stephenson K, Neuenschwander PF, Kurdowska AK (2013) The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women. Int J Pharm Compd 17(1):74–85PubMed
11.
Zurück zum Zitat Hitchcock CL, Prior JC (2012) Oral micronized progesterone for vasomotor symptoms—a placebo-controlled randomized trial in healthy postmenopausal women. Menopause 19(8):886–893CrossRef Hitchcock CL, Prior JC (2012) Oral micronized progesterone for vasomotor symptoms—a placebo-controlled randomized trial in healthy postmenopausal women. Menopause 19(8):886–893CrossRef
12.
Zurück zum Zitat Whelan AM, Jurgens TM, Trinacty M (2013) Bioidentical progesterone cream for menopause-related vasomotor symptoms: is it effective? Ann Pharmacother 47(1):112–116CrossRef Whelan AM, Jurgens TM, Trinacty M (2013) Bioidentical progesterone cream for menopause-related vasomotor symptoms: is it effective? Ann Pharmacother 47(1):112–116CrossRef
13.
Zurück zum Zitat de Villiers TJ, Pines A, Panay N, Gambacciani M, Archer DF, Baber RJ et al (2013) Updated 2013 international menopause society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 16(3):316–337CrossRef de Villiers TJ, Pines A, Panay N, Gambacciani M, Archer DF, Baber RJ et al (2013) Updated 2013 international menopause society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 16(3):316–337CrossRef
14.
Zurück zum Zitat Antoniou G, Kalogirou D, Karakitsos P, Antoniou D, Kalogirou O, Giannikos L (1997) Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses. Maturitas 26(2):103–111CrossRef Antoniou G, Kalogirou D, Karakitsos P, Antoniou D, Kalogirou O, Giannikos L (1997) Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses. Maturitas 26(2):103–111CrossRef
15.
Zurück zum Zitat Cicinelli E, Borraccino V, Petruzzi D, Mazzotta N, Cerundolo ML, Schonauer LM (1996) Pharmacokinetics and endometrial effects of the vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women. Fertil Steril 65(4):860–862CrossRef Cicinelli E, Borraccino V, Petruzzi D, Mazzotta N, Cerundolo ML, Schonauer LM (1996) Pharmacokinetics and endometrial effects of the vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women. Fertil Steril 65(4):860–862CrossRef
16.
Zurück zum Zitat Di Carlo C, Tommaselli GA, Gargano V, Savoia F, Bifulco G, Nappi C (2010) Transdermal estradiol and oral or vaginal natural progesterone: bleeding patterns. Climacteric 13(5):442–446CrossRef Di Carlo C, Tommaselli GA, Gargano V, Savoia F, Bifulco G, Nappi C (2010) Transdermal estradiol and oral or vaginal natural progesterone: bleeding patterns. Climacteric 13(5):442–446CrossRef
17.
Zurück zum Zitat Ben-Chetrit A, Hochner-Celnikier D, Lindenberg T, Zacut D, Shimonovitz S, Gelber H et al (2005) Vaginal ring delivering estradiol and progesterone: a possible alternative to relieve climacteric symptoms. Isr Med Assoc J 7(5):302–306PubMed Ben-Chetrit A, Hochner-Celnikier D, Lindenberg T, Zacut D, Shimonovitz S, Gelber H et al (2005) Vaginal ring delivering estradiol and progesterone: a possible alternative to relieve climacteric symptoms. Isr Med Assoc J 7(5):302–306PubMed
18.
Zurück zum Zitat de Ziegler D, Ferriani R, Moraes LA, Bulletti C (2000) Vaginal progesterone in menopause: Crinone 4 % in cyclical and constant combined regimens. Hum Reprod 15(Suppl 1):149–158CrossRef de Ziegler D, Ferriani R, Moraes LA, Bulletti C (2000) Vaginal progesterone in menopause: Crinone 4 % in cyclical and constant combined regimens. Hum Reprod 15(Suppl 1):149–158CrossRef
19.
Zurück zum Zitat Fernandez-Murga L, Hermenegildo C, Tarin JJ, Garcia-Perez MA, Cano A (2012) Endometrial response to concurrent treatment with vaginal progesterone and transdermal estradiol. Climacteric 15(5):455–459CrossRef Fernandez-Murga L, Hermenegildo C, Tarin JJ, Garcia-Perez MA, Cano A (2012) Endometrial response to concurrent treatment with vaginal progesterone and transdermal estradiol. Climacteric 15(5):455–459CrossRef
20.
Zurück zum Zitat Cicinelli E, de Ziegler D, Galantino P, Pinto V, Barba B, Morgese S et al (2002) Twice-weekly transdermal estradiol and vaginal progesterone as continuous combined hormone replacement therapy in postmenopausal women: a 1-year prospective study. Am J Obstet Gynecol 187(3):556–560CrossRef Cicinelli E, de Ziegler D, Galantino P, Pinto V, Barba B, Morgese S et al (2002) Twice-weekly transdermal estradiol and vaginal progesterone as continuous combined hormone replacement therapy in postmenopausal women: a 1-year prospective study. Am J Obstet Gynecol 187(3):556–560CrossRef
21.
Zurück zum Zitat Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV (1994) Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 62(3):485–490CrossRef Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV (1994) Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 62(3):485–490CrossRef
22.
Zurück zum Zitat Cicinelli E, de Ziegler D, Alfonso R, Nicoletti R, Bellavia M, Colafiglio G (2005) Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3-year pilot study. Fertil Steril 83(6):1859–1863CrossRef Cicinelli E, de Ziegler D, Alfonso R, Nicoletti R, Bellavia M, Colafiglio G (2005) Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3-year pilot study. Fertil Steril 83(6):1859–1863CrossRef
23.
Zurück zum Zitat Noe G, Sitruk-Ware R, Zegers-Hochschild F, Variano B, Montero JC, Arriagada P et al (2010) Endometrial effect of progesterone delivered by vaginal rings in estrogen-treated postmenopausal women. Climacteric 13(5):433–441CrossRef Noe G, Sitruk-Ware R, Zegers-Hochschild F, Variano B, Montero JC, Arriagada P et al (2010) Endometrial effect of progesterone delivered by vaginal rings in estrogen-treated postmenopausal women. Climacteric 13(5):433–441CrossRef
24.
Zurück zum Zitat Suvanto-Luukkonen E, Sundstrom H, Penttinen J, Kauppila A, Rutanen EM (1995) Insulin-like growth factor-binding protein-1: a biochemical marker of endometrial response to progestin during hormone replacement therapy. Maturitas 22(3):255–262CrossRef Suvanto-Luukkonen E, Sundstrom H, Penttinen J, Kauppila A, Rutanen EM (1995) Insulin-like growth factor-binding protein-1: a biochemical marker of endometrial response to progestin during hormone replacement therapy. Maturitas 22(3):255–262CrossRef
25.
Zurück zum Zitat Ferrero S, Gerbaldo D, Fulcheri E, Cristoforoni P (2002) Vaginal micronized progesterone in continuous hormone replacement therapy. A prospective randomized study. Minerva Ginecol 54(6):519–530PubMed Ferrero S, Gerbaldo D, Fulcheri E, Cristoforoni P (2002) Vaginal micronized progesterone in continuous hormone replacement therapy. A prospective randomized study. Minerva Ginecol 54(6):519–530PubMed
26.
Zurück zum Zitat Ross D, Cooper AJ, Pryse-Davies J, Bergeron C, Collins WP, Whitehead MI (1997) Randomized, double-blind, dose-ranging study of the endometrial effects of a vaginal progesterone gel in estrogen-treated postmenopausal women. Am J Obstet Gynecol 177(4):937–941CrossRef Ross D, Cooper AJ, Pryse-Davies J, Bergeron C, Collins WP, Whitehead MI (1997) Randomized, double-blind, dose-ranging study of the endometrial effects of a vaginal progesterone gel in estrogen-treated postmenopausal women. Am J Obstet Gynecol 177(4):937–941CrossRef
27.
Zurück zum Zitat Vilodre LC, Osorio Wender MC, Sisson de Castro JA, dos Reis FM, Ruschel S, Magalhaes JA, et al (2003) Endometrial response to a cyclic regimen of percutaneous 17beta-estradiol and low-dose vaginal micronized progesterone in women with mild-to-moderate hypertension. Gynecol Endocrinol 17(4):323–328CrossRef Vilodre LC, Osorio Wender MC, Sisson de Castro JA, dos Reis FM, Ruschel S, Magalhaes JA, et al (2003) Endometrial response to a cyclic regimen of percutaneous 17beta-estradiol and low-dose vaginal micronized progesterone in women with mild-to-moderate hypertension. Gynecol Endocrinol 17(4):323–328CrossRef
28.
Zurück zum Zitat Suvanto-Luukkonen E, Malinen H, Sundstrom H, Penttinen J, Kauppila A (1998) Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone. Acta Obstet Gynecol Scand 77(7):758–763CrossRef Suvanto-Luukkonen E, Malinen H, Sundstrom H, Penttinen J, Kauppila A (1998) Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone. Acta Obstet Gynecol Scand 77(7):758–763CrossRef
29.
Zurück zum Zitat Moyer DL, de Lignieres B, Driguez P, Pez JP (1993) Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes. Fertil Steril 59(5):992–997CrossRef Moyer DL, de Lignieres B, Driguez P, Pez JP (1993) Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes. Fertil Steril 59(5):992–997CrossRef
30.
Zurück zum Zitat Gillet JY, Andre G, Faguer B, Erny R, Buvat-Herbaut M, Domin MA et al (1994) Induction of amenorrhea during hormone replacement therapy: optimal micronized progesterone dose. A multicenter study. Maturitas 19(2):103–115CrossRef Gillet JY, Andre G, Faguer B, Erny R, Buvat-Herbaut M, Domin MA et al (1994) Induction of amenorrhea during hormone replacement therapy: optimal micronized progesterone dose. A multicenter study. Maturitas 19(2):103–115CrossRef
31.
Zurück zum Zitat Jondet M, Maroni M, Yaneva H, Brin S, Peltier-Pujol F, Pelissier C (2002) Comparative endometrial histology in postmenopausal women with sequential hormone replacement therapy of estradiol and, either chlormadinone acetate or micronized progesterone. Maturitas 41(2):115–121CrossRef Jondet M, Maroni M, Yaneva H, Brin S, Peltier-Pujol F, Pelissier C (2002) Comparative endometrial histology in postmenopausal women with sequential hormone replacement therapy of estradiol and, either chlormadinone acetate or micronized progesterone. Maturitas 41(2):115–121CrossRef
32.
Zurück zum Zitat Hodis HN, Mack WJ, Shoupe D, Azen SP, Stanczyk FZ, Hwang-Levine J et al (2015) Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis. Menopause 22(4):391–401CrossRef Hodis HN, Mack WJ, Shoupe D, Azen SP, Stanczyk FZ, Hwang-Levine J et al (2015) Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis. Menopause 22(4):391–401CrossRef
33.
Zurück zum Zitat Leonetti HB, Wilson KJ, Anasti JN (2003) Topical progesterone cream has an antiproliferative effect on estrogen-stimulated endometrium. Fertil Steril 79(1):221–222CrossRef Leonetti HB, Wilson KJ, Anasti JN (2003) Topical progesterone cream has an antiproliferative effect on estrogen-stimulated endometrium. Fertil Steril 79(1):221–222CrossRef
34.
Zurück zum Zitat Leonetti HB, Landes J, Steinberg D, Anasti JN (2005) Transdermal progesterone cream as an alternative progestin in hormone therapy. Altern Ther Health Med 11(6):36–38PubMed Leonetti HB, Landes J, Steinberg D, Anasti JN (2005) Transdermal progesterone cream as an alternative progestin in hormone therapy. Altern Ther Health Med 11(6):36–38PubMed
35.
Zurück zum Zitat Vashisht A, Wadsworth F, Carey A, Carey B, Studd J (2005) Bleeding profiles and effects on the endometrium for women using a novel combination of transdermal oestradiol and natural progesterone cream as part of a continuous combined hormone replacement regime. BJOG 112(10):1402–1406CrossRef Vashisht A, Wadsworth F, Carey A, Carey B, Studd J (2005) Bleeding profiles and effects on the endometrium for women using a novel combination of transdermal oestradiol and natural progesterone cream as part of a continuous combined hormone replacement regime. BJOG 112(10):1402–1406CrossRef
36.
Zurück zum Zitat Wren BG, McFarland K, Edwards L (1999) Micronised transdermal progesterone and endometrial response. Lancet 354(9188):1447–1448CrossRef Wren BG, McFarland K, Edwards L (1999) Micronised transdermal progesterone and endometrial response. Lancet 354(9188):1447–1448CrossRef
37.
Zurück zum Zitat Wren BG, McFarland K, Edwards L, O’Shea P, Sufi S, Gross B et al (2000) Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women. Climacteric 3(3):155–160CrossRef Wren BG, McFarland K, Edwards L, O’Shea P, Sufi S, Gross B et al (2000) Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women. Climacteric 3(3):155–160CrossRef
Metadaten
Titel
Bioidentische Hormone
verfasst von
Prof. Dr. med. Petra Stute
Publikationsdatum
15.11.2019
Verlag
Springer Vienna
Erschienen in
Journal für Gynäkologische Endokrinologie/Schweiz / Ausgabe 4/2019
Print ISSN: 1995-6924
Elektronische ISSN: 2520-8500
DOI
https://doi.org/10.1007/s41975-019-00124-0

Weitere Artikel der Ausgabe 4/2019

Journal für Gynäkologische Endokrinologie/Schweiz 4/2019 Zur Ausgabe

Orthomolekulare Medizin

Diagnostik der Mikronährstoffe

Der rätselhafte Fall

Der rätselhafte Fall

Blick über den Tellerrand

Sport in den Wechseljahren

Éditorial

Éditorial

Neues aus der Schweizerischen Menopausengesellschaft/SMG

Neues aus der Schweizerischen Menopausengesellschaft/SMG